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Abstract
Background: Improved outcomes for normoglycemic patients suffering acute myocardial infarction (AMI) over the
last decade have not been matched by similar improvements in mortality for diabetic patients despite similar levels
of baseline risk and appropriate medical therapy. Two of the major determinants of poor outcome following AMI
are infarct size and left ventricular (LV) dysfunction.
Methods: Ninety-three patients with first AMI were studied. 22 patients had diabetes mellitus (DM) based on prior
history or admission blood glucose ≥11.1 mmol/l. 13 patients had dysglycemia (admission blood glucose ≥7.8
mmol/l but <11.1 mmol/l) and 58 patients had normoglycemia (admission blood glucose <7.8 mmol/l). Patients
underwent cardiac magnetic resonance (CMR) imaging at index presentation and median follow-up of 11 months.
Cine imaging assessed LV function and late gadolinium contrast-enhanced imaging was used to quantify infarct
size. Clinical outcome data were collected at 18 months median follow-up.
Results: Patients with dysglycemia and DM had larger infarct sizes by CMR than normoglycemic patients; at
baseline percentage LV scar (mean (SD)) was 23.0% (10.9), 25.6% (12.9) and 15.8% (10.3) respectively (p = 0.001),
and at 11 months percentage LV scar was 17.6% (8.9), 19.1% (9.6) and 12.4% (7.8) (p = 0.017). Patients with
dysglycemia and DM also had lower event-free survival at 18 months (p = 0.005).
Conclusions: Patients with dysglycemia or diabetes mellitus sustain larger infarct sizes than normoglycemic
patients, as determined by CMR. This may, in part, account for their adverse prognosis following AMI.
Introduction
The presence of elevated blood glucose levels, diabetes
mellitus (DM), or both, contributes to more than 3 mil-
lion cardiovascular deaths worldwide each year [1].
Patients with DM have higher mortality after acute
myocardial infarction (AMI) than non-diabetic patients
[2]. Moreover, patients with abnormal glucose tolerance
at the time of AMI have a high subsequent cardiovascu-
lar event rate, comparable to patients with a previous
history of DM [3,4].
Alegria and colleagues have highlighted many potential
reasons why patients with impaired glucose tolerance
and DM have a high cardiovascular event rate [5]. These
include a greater degree of coronary artery atheroma [6],
intrinsic systolic and diastolic left ventricular (LV) dys-
function [7,8], impaired recruitment of collateral vessels
[9], a higher rate of reinfarction [10], impaired ischemic
preconditioning [11], reduced myocardial perfusion with
thrombolysis and primary angioplasty [12] and underuse
of evidence-based therapies [13].
Two of the major determinants of poor outcome fol-
lowing AMI are size of infarction and subsequent LV
dysfunction [14]. Cardiovascular magnetic resonance
(CMR) can be used to accurately image the extent of
both acute and chronic myocardial infarction using the
technique of late gadolinium enhancement (LGE) [15].
The high spatial resolution of LGE-CMR has been
shown to detect subendocardial infarction better than
single photon emission computed tomography (SPECT)
[16]. CMR also provides accurate and reproducible
assessment of cardiac function such that it is now the
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tion [17].
The aims of this study were: to determine whether
there is a significant difference in infarct size and LV
remodeling following AMI between non-diabetic sub-
jects and those with dysglycemia or established DM, and
to assess the impact of glycemic status on prognosis.
Materials and methods
Subjects
Ninety-seven patients with first presentation AMI were
prospectively recruited into the study between January
2004 and December 2005. Four patients were unable to
complete CMR imaging due to claustrophobia. There-
fore, the study population consisted of ninety-three
patients (79 men and 14 women, mean age 58 years,
range 30-78 years). The study was approved by the insti-
tutional Research Ethics Committee and complied with
the Declaration of Helsinki; written informed consent
was obtained from all patients. Patients were recruited
consecutively if they met the inclusion criteria of first
presentation AMI and were willing to give consent. The
diagnosis of AMI was based on previously published
consensus criteria [18]. Patients were excluded from the
s t u d yi ft h e yh a dap r e v i o u sh i s t o r yo fa c u t ec o r o n a r y
syndrome, coronary artery revascularization (percuta-
neous coronary intervention (PCI) or coronary artery
bypass graft surgery) or any contraindication to MR
imaging. Further exclusion criteria included age <18 or
>79 years and severe renal failure (defined as estimated
glomerular filtration rate <30 ml/min/1.73 m
2).
All patients had plasma samples for random glucose
measured by the glucose oxidase/Trinders method
(Bayer ADVIA 1650/2400 systems, Bayer plc, Newbury,
UK). Samples were taken at the time of hospital admis-
sion and a glucose level ≥11.1 mmol/l was considered as
a new diagnosis of DM, in accordance with the guide-
lines of the American Diabetes Association [19]. Patients
with a previous history of DM were also categorised into
the DM group, regardless of their admission blood glu-
cose level. Patients with a blood glucose level ≥7.8
mmol/l and <11.1 mmol/l were categorised as having
peri-infarct dysglycemia. Patients with an admission
blood glucose <7.8 mmol/l were considered as having
normoglycemia. All patients had 18-month follow-up
for clinical MACE (Major Adverse Cardiovascular
Events; defined as cardiovascular death, recurrent myo-
cardial infarction, coronary revascularization or hospital
admission for cardiovascular cause).
CMR protocol
All patients underwent CMR during their index admis-
sion. A follow up CMR study, using the identical imaging
protocol, was performed after a median of 11 months to
assess LV remodeling. Patients were studied supine in a
1.5 Tesla scanner (Philips Medical Systems, Best, The
Netherlands) equipped with ‘Master’ gradients (30 mT/m
peak gradients; 150 mT/m/ms slew rate) and a 5-element
cardiac phased array receiver coil. Cine imaging covering
the whole heart in 10-12 parallel short axis slices was
performed using a steady state free precession (SSFP)
pulse sequence (echo time (TE) 1.4 msec; repetition time
(TR) 2.8 msec; flip angle 55°, spatial resolution 2 × 2 ×
7 mm, 18 phases per cardiac cycle). A cumulative dose of
0.2 mmol/kg of Gadolinium-DTPA (Dimeglumine gado-
pentetate, Magnevist, Schering AG, Germany) was admi-
nistered using a power injector (Spectris MR injection
system, Medrad, USA). LGE images were acquired ten to
fifteen minutes after contrast injection with an inversion-
recovery segmented k-space gradient-echo pulse
sequence with a non-selective 180° prepulse (TE 3.8
msec; TR 7.5 msec; flip angle 15°, spatial resolution 1.8 ×
1.8 × 10 mm). The inversion time (TI) was adjusted to
null the signal intensity from normal myocardium. Ten
to 12 short axis slices were obtained.
CMR analysis
CMR analysis was performed off-line using commercial
s o f t w a r e( M a s s6 . 0 ,M e d i s ,T h eN e t h e r l a n d s ) ,b yt w o
experienced observers blinded to clinical details. In
order to quantify LV mass and volumes, epicardial and
endocardial contours were traced by manual planimetry
on each short axis slice at end-diastole and end-systole.
Using the summation of discs method, LV mass (g) was
calculated from the total volume of myocardium at end-
diastole multiplied by the myocardial density 1.05 g/ml.
LGE images were displayed on a grey scale so as to opti-
mally distinguish infarcted tissue (white) from normal
myocardium (black) and the blood pool. Infarcted tissue
was defined as areas with late gadolinium hyperenhance-
ment. These regions were identified and then quantified
using a semi-automated algorithm. Areas of hyperen-
hancement were defined as myocardium with a signal
intensity >2 SD above the mean signal intensity of the
remote normal myocardium [20] (Figure 1). The mass
of infarcted myocardium was then automatically calcu-
lated. Transmural infarction was defined as the presence
of any myocardial segment with >75% transmural extent
of scar tissue on LGE images [16]. The presence of
microvascular obstruction (MO) was also assessed in
each patient. MO on LGE imaging was defined as a
region of subendocardial hypoenhancement within the
hyperenhanced region.
Statistical analysis
The present study is an analysis of observational data so
no formal power calculation to estimate sample size was
performed prior to commencement. Statistical analysis
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Chicago, USA. Two-sided p values ≤0.05 were consid-
ered to be statistically significant. Continuous CMR data
are summarized as mean (standard deviation, SD) and
categorical data as numbers (percentages). Continuous
data between groups were compared using two sample
t tests or one-way analysis of variance (ANOVA) tests
with Bonferroni correction. Categorical data were ana-
lysed using Chi-squared tests. Event-free survival was
calculated from the date of acute infarction to clinical
outcome (MACE) occurrence. Patients who were lost to
follow-up or did not experience an event were treated
as censored. A log-rank test was used to compare the
three groups (normoglycemia, dysglycemia, and dia-
betic), hazard ratios were estimated using a Cox propor-
tional hazards model and Kaplan-Meier survival plots
are presented.
Results
Ninety-three patients completed baseline CMR at a
median of 3 days (interquartile range (IQR), 3 to 4 days)
from the index presentation. Seventy patients had fol-
low-up CMR scans at a median of 328 days (IQR 191 to
382 days) from their index event. 13 patients declined
the repeat scan, 4 patients relocated, 4 patients failed to
attend and 2 patients died prior to follow up.
Baseline characteristics
Twenty-two (24%) of the 93 patients were categorized
into the DM group based on known clinical history of
DM or the finding of a random blood glucose ≥11.1
mmol/L at the time of their hospital admission. 13/93
patients (14%) were categorized into the dysglycemia
group on account of an admission blood glucose ≥7.8
mmol/l and <11.1 mmol/l. 58/93 patients (62%) were
categorized into the normoglycemia group on the basis
of an admission glucose <7.8 mmol/l. Clinical character-
istics for patients categorized by glycemic status are pro-
vided in Table 1. There were no significant differences in
terms of age, gender, cardiovascular risk factors, infarct
location or Killip classification of heart failure between
the three groups. Patients in the dysglycemia group and
Figure 1 An example of infarct contouring for quantification. Late gadolinium enhanced short-axis slice through the left ventricle (LV).
Green contour delineates epicardial LV border and red contour delineates endocardial LV border. Pink shaded area demarcates the area of late
gadolinium hyperenhancement (i.e. signal intensity >2 SD of remote normal myocardium) which denotes myocardial infarct scar.
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than the normoglycemia group (mean (SD) 5.2 (1.04) vs.
4.7 (0.76) vs. 5.6 (0.9) mmol/l respectively; overall p <
0.001). These differences are most likely due to the
higher incidence of pre-hospital use of statin therapy in
the dysglycemia and DM groups. Of the 93 recruited
patients, 71 suffered ST-elevation myocardial infarctions
(STEMI) and were treated with thrombolysis, which was
the standard therapy in our hospital at the time of study
recruitment. The remaining patients (n = 22) had non-
STEMI and were treated with optimal medical therapy
followed by selective invasive coronary angiography if
deemed high risk. Invasive coronary angiography and
subsequent coronary revascularisation if appropriate, was
performed if patients became clinically unstable or
demonstrated evidence of myocardial ischemia either at
rest or during supervised stress testing.
CMR characteristics
Patients with dysglycemia and DM had larger infarct
sizes as determined by LGE-CMR, than those with nor-
moglycemia, both at baseline (mean (SD)% LV scar 23.0
(10.9), 25.6 (12.9) and 15.8 (10.3) respectively; overall
p = 0.001) and at 11 months after presentation (mean
(SD)% LV scar 17.6 (8.9), 19.1 (9.6) and 12.4 (7.8)
respectively; overall p = 0.017) (Figure 2). This was
reflected in the peak CK measurements following AMI
which were significantly higher in the dysglycemia and
DM groups than the normoglycemia group (mean (SD)
2141 (1302), 2722 (1841) and 1542 (1151) U/l respec-
tively; overall p = 0.003) (Figure 3). A greater proportion
of patients with dysglycemia (12/13 (92%)) and diabetes
mellitus (21/22 (95%)) had transmural infarctions
(defined as >75% transmural extent of scar) when com-
pared to patients with normoglycemia (44/58 (76%)).
However, these difference were not significant (overall
p = 0.09). Similarly, there were no significant differences
in the proportions of patients with MO between
the three groups (dysglycemia (6/13 (46%)) vs. diabetes
(10/22 (45%)) vs. normoglycemia (19/58 (33%)), overall
p = 0.10).
There were no significant differences in LV ejection
fraction (LVEF) between the three groups at baseline
(mean (SD)% LVEF, dysglycemia 45 (8.5) vs. DM 43.4
(8.1) vs. normoglycemia 46.9 (7.1); overall p = 0.18) and
at 11 months (mean (SD)% LVEF, dysglycemia 50.2 (7.6)
vs. DM 49.4 (7.2) vs. normoglycemia 52.9 (8.2); overall
p = 0.26) (Figure 4). The CMR results at baseline and at
11 months are summarized in Tables 2 and 3.
Clinical cardiovascular outcome
Of the 58 patients with normoglycemia, 15 (25.9%) suf-
fered at least one MACE, compared to 8 of the 13
patients (61.5%) with dysglycemia and 8 of the 22
patients (36.4%) in the DM group. From the entire cohort
there were 3 deaths, 6 recurrent MIs, 11 revasculariza-
tions (9 PCI and 2 CABG), and 11 readmissions to hospi-
tal for a cardiovascular cause. There was a significant








Age (years) 57 (10.7) 61 (11.1) 61 (10.8) 0.19
Male 83% 85% 91% 0.70
Hypertension 14% 15% 32% 0.22
Smoking 76% 69% 73% 0.55
Family History 40% 46% 45% 0.87
STEMI 69% 85% 91% 0.09
Territory of infarction Anterior 43% 46% 45%
0.94
Inferior 47% 54% 55%
Killip class I 81% 77% 64%
II 9% 0 18% 0.26
III 10% 23% 18%
Heart rate 73 (15.3) 78 (19) 81 (18.4) 0.14
Systolic BP (mmHg) 135 (25.6) 135 (17.4) 139 (23.4) 0.76
Diastolic BP (mmHg) 76 (17.3) 73 (15.7) 77 (15.9) 0.77
Peak CK (U/l) 1542 (1151) 2141 (1302) 2722 (1841) 0.003
Creatinine (μmol/l) 101 (13.6) 102 (11.7) 107 (17.7) 0.27
Cholesterol (mmol/l) 5.6 (0.9) 5.2 (1.0) 4.7 (0.76) <0.001
Triglycerides (mmol/l) 1.8 (0.9) 2.1 (1.1) 1.6 (0.9) 0.40
Glucose (mmol/l) 6.3 (0.9) 9.1 (1.2) 12.5 (2.9) <0.001
DM = diabetes mellitus, CK = creatine kinase, BP = blood pressure.
Data represented as percentages or mean (SD).
o
)
Mather et al. Journal of Cardiovascular Magnetic Resonance 2010, 12:61
http://www.jcmr-online.com/content/12/1/61
Page 4 of 10difference in overall event-free survival among the three
groups of patients (log-rank test, p = 0.005) (Figure 5).
Patients with dysglycemia were significantly more likely
to experience an event at any time than normoglycemic
patients, Hazard Ratio (HR) 3.82 (95% CI: 1.61, 9.06), but
t h e r ew a sn os i g n i f i c a n td i f f e r e n c ei ns u r v i v a lb e t w e e n
patients with DM and normoglycemia, HR 1.48 (95% CI:
0.63, 3.50). When all patients with DM and peri-infarct
dysglycemia were combined and compared to the normo-
glycemia group, as before 15/58 (25.9%) of those with
normoglycemia suffered at least one MACE compared to
16/35 (45.7%) of those with DM and peri-infarct dysgly-
cemia (c2 = 3.87; p < 0.05).
Discussion
In this study, we found that myocardial infarct size as
measured by CMR is significantly larger in patients with
dysglycemia or DM than in normoglycemic patients. This
finding was supported by higher peak CK levels following
AMI in the hyperglycemic subjects. Patients with dysglyce-
mia and DM also had lower LV ejection fractions although
these differences were not statistically significant. The dif-
ferences in CMR findings between the three groups were
consistent at 11 months follow-up.
Diabetes mellitus is firmly established as a strong inde-
pendent risk factor for cardiovascular death and recur-
rent myocardial ischemia [21] and the prevalence of type
2 DM is predicted to rise over the next quarter of a cen-
tury [22]. DM is also recognized as a surrogate marker
for underlying cardiovascular disease. A recent Danish
population-based study demonstrated that the excess car-
diovascular risk associated with diabetes was not necessa-
rily confined to middle-aged and older patients and that
the very presence of medically-treated diabetes raised a
diabetic individual’s risk to that of a non-diabetic subject
with a prior myocardial infarction [23].
Improved outcomes for normoglycemic patients suf-
fering AMI over the last decade have not been matched
by similar improvements in mortality for diabetic
patients despite similar levels of baseline risk and appro-
priate medical therapy [24,25]. Patients with DM are
known to have higher mortality in both the short and
long term following AMI when compared with non-dia-
betic patients [26]. Furthermore, admission hyperglyce-
mia appears to be an even stronger predictor of
mortality in those patients without a prior diagnosis of
DM [4,27]. Similarly in a study of AMI, amongst
patients with no prior history of diabetes, a 1% absolute
Figure 2 Boxplot demonstrating% LV scar at baseline and at median follow up 11 months (n = 70) according to glycemic status.T h eb o x e s
represent the interquartile range and the lines denote the median. The error bars represent the 95% confidence intervals. (LV = left ventricular).
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Page 5 of 10Figure 3 Graph demonstrating the peak CK levels according to glycemic status. The error bars represent the 95% confidence intervals.
(CK = creatine kinase).
Figure 4 Graph demonstrating mean LVEF% at baseline and at median follow up 11 months (n = 70) according to glycemic status.
The error bars represent the 95% confidence intervals. (LVEF = left ventricular ejection fraction).
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24% increase in mortality [28].
The majority of studies that have investigated infarct
size in diabetic patients have measured cardiac enzyme
levels as the principal method of quantification. How-
ever, all of these studies, except one [29], have shown
similar or smaller infarct size in diabetic patients. Enzy-
matic assessment of infarct size has its limitations, parti-
cularly in patients who have had reperfusion therapy
[30]. It is recognised that successful reperfusion can
increase the washout and hence the peak level of cardiac
enzymes and therefore, paradoxically, lower peak
enzyme levels may be associated with poorer reperfusion
and possibly larger infarcts.
Alegria et al, used SPECT imaging following AMI in
diabetic subjects and found significantly larger infarct
size and reduced LVEF in patients with diabetes than
non-diabetic patients [5]. One explanation given for this
finding was that there was a higher incidence of previous
MI in the diabetic population and that SPECT could not
distinguish acute from chronic infarction. Our results are
consistent with the previous data by Alegria, but our
study population comprised only patients with a first epi-
sode of AMI and well-matched baseline clinical charac-
teristics. There was no evidence, in any patient, of
previous myocardial infarction in any other coronary
artery territory on LGE imaging. By using the much
more accurate technique of CMR to measure LV func-
tion and infarct size, we were able to demonstrate that
patients with dysglycemia and DM had significantly lar-
ger infarcts which were associated with higher peak CK
levels and a trend towards lower LVEF, when compared
Table 2 CMR findings at baseline







End diastolic volume (ml) 181 (37) 162 (37) 182 (25) 0.18
End systolic volume (ml) 97 (28) 91 (30) 103 (22) 0.39
Ejection fraction (%) 47 (7) 45 (8) 43 (8) 0.18
LV mass (g) 119 (29) 121 (31) 117 (19) 0.90
LV infarct size (%) 16 (10) 23 (11) 26 (13) 0.001
CMR = cardiovascular magnetic resonance, LV = left ventricular, other abbreviations as in Table 1.
Data represented as mean (SD).










Baseline 178 (37) 159 (28) 179 (24)
Follow-up 177 (35) 161 (40) 183 (36) 0.31
P-value baseline vs. follow-up NS NS NS
LVESV (ml)
Baseline 95 (26) 89 (23) 99 (23)
Follow-up 85 (27) 81 (30) 94 (29) 0.41
P-value baseline vs. follow-up <0.001 NS NS
Ejection fraction (%)
Baseline 47 (6) 44 (7) 45 (9)
Follow-up 53 (8) 50 (7) 49 (7) 0.26
P-value baseline vs. follow-up <0.001 <0.05 <0.05
LV mass (g)
Baseline 117 (29) 115 (21) 113 (18)
Follow-up 99 (23) 95 (20) 102 (19) 0.74
P-value baseline vs. follow-up <0.001 <0.001 <0.001
%LV-scar
Baseline 15 (9) 23 (11) 25 (14)
Follow-up 12 (8) 18 (9) 19 (10) 0.02
P-value baseline vs. follow-up <0.001 <0.05 <0.05
Data represented as mean (SD).
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relationship of CMR infarct size to the peak CK as shown
by Younger et al [31]. The trend towards reduced LVEF
in DM may be due to the larger infarct size or possibly
other factors that were not recorded such as angiographic
evidence of more extensive coronary artery disease or
impaired myocardial perfusion. These results also sup-
port previous CMR data demonstrating a strong relation-
ship between impaired glucose metabolism and
myocardial damage in STEMI patients [32].
The 18-month outcome data from this study are parti-
cularly interesting and highlight an important message
regarding risk stratification of AMI patients. We have
shown that patients with an admission glucose level ≥7.8
mmol/l have a significantly reduced event-free survival
f r o mM A C E .T h i si sc o n s i s t e n tw i t hr e c e n tf i n d i n g st h a t
in-hospital glucose levels are a stronger predictor of death
than diabetes history and that patients with AMI with an
admission glucose ≥8 mmol/l have a very high risk of
death regardless of diabetes history [33]. Perhaps of greater
interest is the fact that 18-month event free survival was
actually lowest in those considered to have impaired glu-
cose tolerance compared to those with DM or normogly-
cemia. Indeed, this group had smaller infarct sizes but
worse outcome than those with DM. It may have been
that those considered frankly diabetic had more aggressive
secondary prevention and attention to glycemic control,
whilst those with impaired glucose tolerance were actually
under-diagnosed for DM. This would be in keeping with
the findings from Norhammar et al, who showed in their
series of AMI patients with random glucose levels below
11.1 mmol/L, that approximately one-third of patients had
overt DM and a further third had impaired glucose toler-
ance at discharge and 3 months later [21]. Clearly infarct
size and ventricular function/remodeling are important
determinants of outcome, with larger infarcts expected to
manifest as greater risk of sudden cardiac death (arrhyth-
mia) and heart failure. However, other pathophysiological
mechanisms of infarct healing may be important including
residual ischemic burden (hibernation), microvascular
obstruction and hemorrhage within the infarct core. The
impact of glycemic control on these factors remains to be
determined.
Limitations
We made a pragmatic decision to categorize patients
based on admission blood glucose levels. We acknowl-
edge that more than one measurement of blood glucose
is required to diagnose DM and impaired glucose toler-
ance but nevertheless our data highlight some important
observations. The study population was also relatively
small and a larger sample size would have allowed more
detailed subgroup analyses. Data were not collected
regarding on-going glycometabolic control or HbA1c
levels and therefore we could not assess the significance
of these variables on infarct size or event-free survival.
The study population included patients with ST-elevation
MI and non-ST-elevation MI. Again, a larger population
Figure 5 Kaplan-Meier curves demonstrating event-free survival for all patients subdivided by glycemic status.
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Although primary percutaneous coronary intervention
(PPCI) is now considered the optimum reperfusion strat-
egy for the treatment of STEMI [34], intravenous throm-
bolysis remains the mainstay of therapy for the majority
of patients in the United Kingdom and USA. Therefore,
the findings from this study are directly relevant to cur-
rent cardiological practice, although it is accepted that in
the future PPCI will supercede thrombolysis and this
may have a direct impact on myocardial infarct size.
Conclusions
The results of this study suggest that following AMI,
patients with dysglycemia and DM sustain significantly lar-
ger myocardial infarctions than normoglycemic patients.
This finding may be a significant factor contributing to the
known higher mortality seen in these patients. In addition,
dysglycemia at the time of AMI has a significant adverse
impact on cardiovascular outcome, an effect which
appears more marked even compared to those patients
with diabetes mellitus. Further studies are needed to
explore the significance of glycemic control on infarct size
and ventricular remodeling in order to improve our
understanding of the mechanisms that account for the
adverse outcome in patients with dysglycemia and AMI.
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